AI Health’s Concentration Risk: 5 Firms Hold 76% of Market Value

The burgeoning AI health sector is undeniably a magnet for venture capital, yet beneath the headline-grabbing valuations and rapid advancements lies a critical, often understated, phenomenon: investment concentration risk. While the overall market for AI in healthcare continues its accelerated expansion, a disproportionate share of private market value is consolidating within a select few entities. This creates a top-heavy landscape that demands careful scrutiny from investors looking beyond the immediate hype to sustainable growth and diversified portfolios.

The Concentrated Landscape of AI Health Investment

Our analysis reveals a striking imbalance in the private AI health market. Data from leading industry trackers, including Crunchbase, PitchBook, Rock Health, and CB Insights, consistently points to a significant concentration of capital. Specifically, the top 10 private AI health companies collectively command an impressive $53.5 billion in combined valuation. However, delving deeper into this figure exposes the true extent of concentration: the top 5 companies alone account for $40.6 billion, representing a substantial 76% of that total. This indicates that while the sector appears robust, the lion’s share of perceived value is tied to a very small cohort of players.

This dynamic is further underscored by the outsized valuation of a single entity. OpenEvidence, for instance, contributes 22% of the total value attributed to the top 10 private AI health companies. Such dominance, while indicative of strong investor confidence in specific models, also highlights the potential for market volatility should any of these heavily weighted companies face unforeseen challenges in regulatory navigation, enterprise contract depth, or health-plan expansion signals. The growth metrics we track, such as employer and health-plan relationships and Fortune 500 deployments, become even more critical in assessing the true resilience of these highly valued entities.

Examining the Portfolio: OpenEvidence, Oura, Commure, Abridge, Nabla, Hippocratic AI, and Spring Health

Within this concentrated ecosystem, a few companies stand out, drawing significant investment and shaping the market’s trajectory. OpenEvidence’s commanding position, as noted, is a testament to its perceived potential, likely driven by a strong data moat and early indicators of enterprise contract depth. As of January 2026, OpenEvidence was valued at $12 billion following a $250 million Series D funding round. Similarly, Oura has carved out a significant niche, demonstrating growth through consumer adoption which, in turn, can translate into employer and health-plan expansion signals as wellness programs evolve. Oura was valued at $11 billion in October 2025 and confidentially filed for an IPO in May 2026.

Companies like Commure, Abridge, and Nabla are also part of this upper echelon, each addressing distinct facets of healthcare AI, from infrastructure to clinical documentation and patient engagement. Commure secured a $7 billion valuation in May 2026. Abridge’s valuation reached $5.3 billion as of April 2026. Nabla raised $70 million in a Series C funding round in June 2025, bringing its total funding to $120 million. Their growth trajectories are often fueled by strategic partnerships and the ability to demonstrate clear value propositions to health systems and payers, moving beyond mere technological novelty to tangible ROI. The involvement of influential figures like Vinod Khosla, a prominent venture capitalist known for his early bets on transformative technologies, and Jorge Conde, a respected voice in health tech investment, further validates the perceived potential of these leading companies. Their backing signals a strong belief in the long-term viability and scalability of these AI-native solutions, especially as regulatory scrutiny increases and validated AI health companies are proven to grow faster Rock Health report on AI health investment trends.

Newer entrants such as Hippocratic AI are rapidly gaining traction, demonstrating that even in a concentrated market, innovative approaches can attract substantial capital. Hippocratic AI was valued at $3.5 billion in November 2025 after a $126 million Series C funding round. Spring Health, with its focus on mental health, exemplifies how AI can address critical, underserved areas, securing significant funding by demonstrating clear employer and health-plan expansion signals. Spring Health was valued at $